Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202410 | 0.78 | KDM4E (0.40) | MAPK14KDM4EADORA3ADORA2AADORA1 | |
| SCHEMBL311958 | 0.78 | PARP1 (0.51) | KDM4EGPR3ALDH1A1HPGDTOP2A | |
| SCHEMBL1423662 | 0.75 | TNKS (0.56) | ALDH1A1HPGDTOP2A | |
| SCHEMBL5137072 | 0.75 | KDM4E (0.46) | KDM4EGPR3ALDH1A1HPGDTOP2A | |
| SCHEMBL311168 | 0.75 | KDM4E (0.46) | KDM4EGPR3ALDH1A1HPGDTOP2A | |
| SCHEMBL842044 | 0.75 | QTRT1 (0.51) | KDM4EGPR3ADORA3ALDH1A1HPGD | |
| SCHEMBL10768282 | 0.74 | TNKS (0.58) | KDM4ETOP2A | |
| SCHEMBL1486423 | 0.73 | KDM4E (0.44) | KDM4EGPR3ALDH1A1TOP2AHTT | |
| SCHEMBL20683086 | 0.73 | SMN1; SMN2 (0.43) | MAPK14KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL290937 | 0.73 | KDM4E (0.46) | MAPK14KDM4EALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948173-B1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8377957-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-22 | — | — | US | disclosed |
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088790-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| EP-1948173-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007056112-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | MAPK14 1842/4885KDM4E 2017/4885GPR3 1321/4885 |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | MAPK14 2754/4885KDM4E 2419/4885GPR3 1522/4885 |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | MAPK14 1842/4885KDM4E 2017/4885GPR3 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.